These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 164312)

  • 1. Effects of clofibrate and a fat-modified diet on serum lipids.
    Brown HB; Lewis LA; Page IH
    Clin Pharmacol Ther; 1975 Feb; 17(2):171-8. PubMed ID: 164312
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of vitamin E on serum cholesterol and triglycerides in hyperlipidemic patients treated with diet and clofibrate.
    Leonhardt ET
    Am J Clin Nutr; 1978 Jan; 31(1):100-5. PubMed ID: 202160
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Effect of a clofibrate-inositol nicotinate combination on lipids and lipoproteins in primary hyperlipoproteinemia of types IIa, IV and V].
    Hutt V; Wechsler JG; Klör HU; Ditschuneit H
    Arzneimittelforschung; 1983; 33(5):776-9. PubMed ID: 6683558
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Polyunsaturated meat and dairy products in fat-modified food patterns for hyperlipidemia.
    Brown HB; deWolfe VG; Naito HK; Harper WJ; Palmquist DL
    J Am Diet Assoc; 1976 Sep; 69(3):235-42. PubMed ID: 181413
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pronounced lipoprotein lipid reduction obtained by combined lipid-lowering treatment in patients with atherosclerotic disease.
    Vessby B; Lithell H; Gustafsson IB; Borberg J
    Atherosclerosis; 1979 Aug; 33(4):457-77. PubMed ID: 228684
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clofibrate-induced low density liporotein elevation. Therapeutic implications and treatment by colestipol resin.
    Rose HG; Haft GK; Juliano J
    Atherosclerosis; 1976; 23(3):413-27. PubMed ID: 178325
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cholestyramine, clofibrate and nicotinic acid as single or combined treatment of type IIa and IIb hyperlipoproteinaemia.
    Orö L; Olsson AG; Rössner S; Carlson LA
    Postgrad Med J; 1975; 51(8):suppl 76-81. PubMed ID: 215986
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dose-response effect of single and combined clofibrate (Atromidin) and niceritrol (Perycit) treatment on serum lipids and lipoproteins in type II hyperlipoproteinaemia.
    Olsson AG; Orö L; Rössner S
    Atherosclerosis; 1975; 22(1):91-101. PubMed ID: 1098680
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Colestipol, clofibrate, cholestyramine and combination therapy in the treatment of familial hyperbetalipoproteinaemia.
    Stein EA; Heimann KW
    S Afr Med J; 1975 Jul; 49(31):1252-6. PubMed ID: 168650
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of dietary treatment on the lipid, lipoprotein and fatty acid compositions in type IV familial hypertriglyceridemia.
    Agheli N; Cloarec M; Jacotot B
    Ann Nutr Metab; 1991; 35(5):261-73. PubMed ID: 1776822
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gemfibrozil: effect on serum lipids, lipoproteins, postheparin plasma lipase activities and glucose tolerance in primary hypertriglyceridaemia.
    Nikkilä EA; Ylikahri R; Huttunen JK
    Proc R Soc Med; 1976; 69 Suppl 2(Suppl 2):58-63. PubMed ID: 190608
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hyperlipidemia in coronary heart disease. 3. Evaluation of lipoprotein phenotypes of 156 genetically defined survivors of myocardial infarction.
    Hazzard WR; Goldstein JL; Schrott MG; Motulsky AG; Bierman EL
    J Clin Invest; 1973 Jul; 52(7):1569-77. PubMed ID: 4352458
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clofibrate in type II hyperlipoproteinemia.
    Ditzel J; Bang HO
    Acta Med Scand; 1976; 200(1-2):55-58. PubMed ID: 183462
    [TBL] [Abstract][Full Text] [Related]  

  • 14. One-year trials with halofenate, clofibrate, and placebo.
    Dujovne CA; Azarnoff DL; Huffman DH; Pentikäinen P; Hurwitz A; Shoeman DW
    Clin Pharmacol Ther; 1976 Mar; 19(3):352-9. PubMed ID: 177242
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reduction of plasma lipids, lipoproteins, and apoproteins by dietary fish oils in patients with hypertriglyceridemia.
    Phillipson BE; Rothrock DW; Connor WE; Harris WS; Illingworth DR
    N Engl J Med; 1985 May; 312(19):1210-6. PubMed ID: 3990714
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Replacement of carbohydrate by protein in a conventional-fat diet reduces cholesterol and triglyceride concentrations in healthy normolipidemic subjects.
    Wolfe BM; Piché LA
    Clin Invest Med; 1999 Aug; 22(4):140-8. PubMed ID: 10497712
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Low-fat diet versus low-carbohydrate diet in the treatment of type IV hyperlipoproteinaemia.
    Sommariva D; Scotti L; Fasoli A
    Atherosclerosis; 1978 Jan; 29(1):43-51. PubMed ID: 204316
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Comparative studies on the cholesterol and triglyceride-lowering effect of alpha-methylthyroxine (Skleronorm) and clofibrate (Regelan) in hyperlipoproteinemias of type IIa/b and IV].
    Jantke J; Schwartzkopff W; Zschiedrich M
    Verh Dtsch Ges Inn Med; 1977 Apr 17-21; 83():392-5. PubMed ID: 206057
    [No Abstract]   [Full Text] [Related]  

  • 19. [Treatment of primary hyperlipoproteinemias of type IIB and IV with butylbiguanide and clofibrate (author's transl)].
    Koschinsky T; Gries FA; Schwandt P; Weisweiler P; Hansen W; Nijssen J; Beckmann R
    MMW Munch Med Wochenschr; 1977 May; 119(20):701-4. PubMed ID: 195201
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hypolipidemic effect of tibric acid. A comparison with clofibrate and placebo in type IV hyperlipoproteinemia.
    Bielmann P; Brun D; Moorjani S; Gagnon MA; Tétreault L; Lupien PJ
    Int J Clin Pharmacol Biopharm; 1977 Apr; 15(4):166-71. PubMed ID: 192685
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.